COVID-19 Offerings COVID-19 Research Use Only Offerings COVID-19 Virus Detection

COVID-19 Virus Detection

background pattern

Microfluidics Technology in Infectious Disease Research and Surveillance

In a short period of time, a novel coronavirus (SARS-CoV-2) has impacted our lives, society and health care infrastructure. To address critical needs for clinical research and public health surveillance, Standard BioTools™ products are supporting global laboratory efforts by delivering

  • cost-efficient workflows that minimize reagent consumption using microfluidics technology
  • scalable throughput that enables the testing of >6,000 samples per day
  • flexible panel designs that enable users to easily add, remove or change assays without changing technologies.

Labs around the world have leveraged the benefits of Standard BioTools microfluidics for research and implemented high-throughput lab developed tests (LDT) for SARS-CoV-2 detection.

Whether you are seeking to gain new insights into infectious disease research or public health surveillance or to accelerate therapeutic development, we can help you reach your goal.

Learn more about SARS-CoV-2 mutation detection.

Learn more

 

Webinar: Emergency Testing Platforms Using Research Technologies: Adapting Standard BioTools' Microfluidic GE Platform for a Test for SARS-CoV-2

Emergency Testing Platforms Using Research Technologies: Adapting Standard BioTools' Microfluidic GE Platform for a Test for SARS-CoV-2.

Register to watch


Presenter:

Joel Guthridge, PhD
Assistant Member, Arthritis and Clinical Immunology Research Program
Director of Translational Informatics & Clinical Resources
Director of Human Phenotyping Core and of Biorepository Oklahoma Medical Research Foundation

 

Publications

Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients | Ouyang, Y. et al. Clinical Infectious Diseases 71 (2020): 2,052–2,060.

The authors describe the use of Biomark™ HD in a study focusing on severe COVID-19 infections. The study found decreased T cell populations along with down-regulated gene expression related to T cell activation and differentiation, “which may help to provide effective treatment strategies for COVID-19.”

Available now: Pathogen Detection using the Advanta RT-PCR Kit

Infectious disease research and surveillance play a critical role in improving global health care. Information acquired from research drives public health policy for preventive measures, drug treatment and vaccine development. PCR-based applications such as reverse transcription PCR (RT-PCR) are commonly used to detect viral and bacterial pathogens.

The Advanta RT-PCR Kit—192.24 provides scalable, high-throughput pathogen detection through nanoliter-scale volumes with walkaway automation. Using the 192.24 Dynamic Array™ IFC (integrated fluidic circuit) enables rapid data acquisition of up to 192 samples across 24 targets: up to 4,608 reactions every 35 minutes.

For Research Use Only. Not for use in diagnostic procedures.

 

Advanta RT-PCR Kit—192.24, 10 IFCs

This kit enables probe-based quantitative PCR of 1,920 samples and combines reverse transcription and preamplification in a single step.

Order now

 

Features

Benefits

Proprietary microfluidics technology Nanoliter-volume reactions ensure low cost per sample.
Modular system that allows up to 6,000 samples to be processed in a day Highly scalable to fit laboratory’s needs
Up to 24 molecular targets in a single run Preserve precious sample while providing comprehensive molecular pictures of the sample.
Up to 4,608 datapoints in a single run Save time by accessing more information per run.

background pattern
Large image of Fluidigm's Biomark HD instrument

Biomark HD

With the Biomark HD system, you get reliable production-scale throughput and excellent sensitivity, with a wide variety of sample types and chemistry choices to accommodate the most genomic applications.

Scalable, High-Throughput Viral RNA Detection

Efficient—Maximize your budget with microfluidics technology by using up to 50 times less reagent than traditional PCR methods.

Scalable—Run nearly 6,000 samples in a 24-hour workflow on each Biomark HD and Juno™ system.

Flexible—Detect up to 24 unique pathogens per sample, such as SARS-CoV-2, influenza A and other respiratory disease pathogens.

Download flyer

Learn more about the assay from the quick reference (QR) guide, which describes in detail:

  • The workflow
  • Materials including Standard BioTools and third-party reagents and kits
  • Consumables and equipment
  • Detailed procedures for viral RNA detection

View QR guide

Read full protocol

Get more information

Unless explicitly and expressly stated otherwise, all products are provided for Research Use Only, not for use in diagnostic procedures. Find more information here.